Skip to Content

Pegaspargase Pregnancy and Breastfeeding Warnings

Pegaspargase is also known as: Oncaspar

Medically reviewed on August 4, 2017.

Pegaspargase Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category: C

Animal reproduction studies have not been conducted. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Pegaspargase Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the
drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.

References for breastfeeding information

  1. "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide